Medical technology company Telezon (ASX:TLZ) has announced it has signed an agreement with surgical device and accessory developer GEMU with the aim of commercialising a new needle device.
The non-binding agreement will see the parties work towards commercialisation of the SSB draw-up needle.
But moving forward will depend on the outcome of moulding trials at GEMU's Swiss facilities. If the trials prove successful, the parties will then orchestrate a small volume pilot production run.
Join the CIO Australia group on LinkedIn. The group is open to CIOs, IT Directors, COOs, CTOs and senior IT managers.